Krystal Biotech reported a 473% increase in full-year revenue, driven by VYJUVEK sales, and anticipates European and Japanese regulatory decisions in 2025.
Krystal Biotech reports $83.8 million in product revenue, driven by VYJUVEK sales following its FDA approval for dystrophic epidermolysis bullosa (DEB).
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.